MyoKardia Stock News

Bristol Myers Squibb & Co (NYSE: BMY) has announced that the FDA has extended the decision date for mavacamten. Bristol Myers announced that the date has slid from January 28, 2022, to April 28, 2

Bristol Myers Squibb Co. said Thursday it had a net loss of $10.027 billion, or $4.45 a share, in the fourth quarter, wider than the loss of $1.056 billion, or 55 cents a share, posted in the year-ear

Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused product line

The deal was a big bet on one promising pipeline drug.

EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation

ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients

Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy Registry

Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020

BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250

EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation

MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM and R&D

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in

BMY is taking over MyoKardia for $13 billion. MyoKardia's lead drug could generate peak sales of ~$2 billion, there are other pipeline candidates aimed at treating CV diseases on top of that.

Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David...